ClinicalTrials.gg
CompletedNCT01377844Updated Jul 1, 2021Results posted

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

A Phase 2 interventional study of EGT0001442 and Placebo in Diabetes Mellitus, sponsored by Theracos. Completed at 11 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-07-01.

Sponsored by Theracos · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 3,022 studies in Diabetes Mellitus with a site in United States — 288 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Enrollment
609th of 2,501
288 · median 82
Started
2011
with 146 others
Phase 2
279 of 3,022
16 open now
Registered
1,164th of 3,022
by date

Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 609th largest by enrollment of the 2,501 interventional ones that give a count, is one of 147 that started in 2011, is one of 279 in phase 2, and was the 1,164th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

288 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

283 more — sign in →

All 288 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,022 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy of EGT0001442 in lowering glycosylated Hemoglobin (HbA1c, A laboratory test to diagnose three months average of blood sugar)levels at 24th week from baseline, when compared to placebo group(no diabetic medication given). The secondary aim of the study is to evaluate the efficacy of EGT0001442 in lowering fasting blood glucose at the weeks 2 and 24 and comparing the results with placebo group. This study assess the efficacy of EGT0001442 based on the proportion of subjects who reach the American Diabetes Association (ADA) target of HbA1c of \< 7% in EGT0001442 group and comparison with placebo. The study also evaluates the effect of EGT0001442 on systolic, diastolic pressures, body weight and compare with the respective placebo groups.This study also assess the change from baseline in HbA1c overtime, from week 1 to week 96. Finally, to assess the safety of EGT0001442 in the Type 2 Diabetic patients (adult/maturity onset).

Read the detailed description

EGT0001442 is a compound that may inhibit the effect of other compounds in the body known as sugar transporters. The use of EGT0001442 may enhance the elimination of glucose from the blood by increasing the amount of urine produced. Hence the blood glucose levels are significantly decreased and the efficacy of EGT001442 can be established by assessing the three months average blood glucose levels (HbA1c). Due to the increased urinary output, the effect of EGT001442 on blood pressure levels are also assessed.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • Diabetes mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥18 years old
  • Diagnosed with type 2 diabetes
  • (BMI) ≤ 45 kg/m2
  • between 7 and 10% (inclusive) at screening
  • FPG \<250 mg/dL at screening for subjects not treated with oral anti-diabetic therapies or FPG \<240 mg/dL at screening for subjects treated with anti-diabetic therapies
  • Diabetes currently treated with diet and exercise only or diet and exercise along with one approved oral anti-diabetic agent
  • If taking anti-diabetic medication, dose and regimen must be stable for past 3 months
  • If taking anti-hypertensive medication, dose and regimen must be stable for past 3 months
  • If taking lipid modifying therapy, dose and regimen must be stable for past 3 months
  • Blood glucose \<250 mg/dL based on finger stick blood glucose for all subjects at randomization

Exclusion criteria

Exclusion Criteria:

  • Hemoglobinopathy that affects measurement
  • Current use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor based therapy)
  • Genitourinary tract infection within 6 weeks of screening
  • Greater than 2 episodes of genitourinary tract infection in the past year
  • History of kidney stones, bladder malfunction or other significant risk factor for urinary tract infections
  • , as calculated by the modification of diet in renal disease study equation (MDRD), \< 50 mL/min/1.73 m2
  • Abnormal tests of liver function , AST or ≥ 3x
  • Diagnosis of retinopathy or significant nephropathy (eGFR \< 50 mL/min/1.73 m2
  • Uncontrolled hypertension (systolic blood pressure >160 or diastolic blood pressure >95)
  • Not willing to use effective , if female with
  • \< 2 years
  • (NYHA) Class 4 heart failure
  • Sera positive of , , or positive on drug screen
  • Currently participating in another interventional trial
  • Previous treatment with EGT0001442 or EGT0001474
  • Not able to comply with the study scheduled visits
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    EGT0001442

    EGT0001442 capsule, 20 mg, daily, 96 weeks

    Drug: EGT0001442

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Also known as: Bexagliflozin

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c at 24 Weeks

    Changes from baseline in HbA1c in placebo and treatment group at end of 24 weeks treatment

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Changes in Systolic and Diastolic Blood Pressure at Week 24

    Changes from baseline in systolic and diastolic blood pressure in placebo and treatment group after 24 weeks of treatment

    Time frame: Baseline and Week 24

  2. Changes in Body Weight at Week 24

    Changes from baseline in body weight in placebo and treatment group after 24 weeks of treatment

    Time frame: Baseline and week 24

  3. Change From Baseline in HbA1c Over 96 Weeks Time

    Change from baseline in HbA1c level over 96 weeks in placebo and treatment group. The treatment group was treated with EGT0001442 for 24 weeks.

    Time frame: Baseline and up to 96 weeks

  4. Change From Baseline Over Time in Fasting Plasma Glucose (FPG)

    Changes from baseline in FPG in placebo and treatment group over 24 weeks of treatment

    Time frame: 24 weeks

  5. Percentage of Subjects Achieving HbA1c <7%

    The number and percentage of subjects achieving HbA1c response levels \<7% for the FAS using LOCF is reported

    Time frame: Baseline and up to 96 weeks

07

Results

Posted Jun 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneEGT0001442Placebo
Started145143
Safety population145141
Completed109108
Not completed3635
Withdrew: Withdrawal by subject2528
Withdrew: Protocol violation23
Withdrew: Adverse event30
Withdrew: Physician decision63
Withdrew: Study terminated by sponsor01

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c at 24 Weeks

Changes from baseline in HbA1c in placebo and treatment group at end of 24 weeks treatment

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · percentage of glycated hemoglobin
Change From Baseline in Hemoglobin A1c at 24 Weeks
percentage of glycated hemoglobinEGT0001442Placebo
Change From Baseline in Hemoglobin A1c at 24 Weeks-0.28 ± 0.1940.51 ± 0.200
Statistical analysis
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -0.79 · 95% CI -1.06 to -0.53Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
SecondaryChanges in Systolic and Diastolic Blood Pressure at Week 24

Changes from baseline in systolic and diastolic blood pressure in placebo and treatment group after 24 weeks of treatment

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mm Hg
Changes in Systolic and Diastolic Blood Pressure at Week 24
mm HgEGT0001442Placebo
Systolic blood pressure-8.62 ± 1.903-3.08 ± 1.964
Diastolic blood pressure-3.07 ± 1.223-0.40 ± 1.275
Statistical analysis
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -5.53 · 95% CI -8.02 to -3.04Based on analysis of covariance, including treatment group, baseline systolic BP, baseline HbA1c category, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = 0.0015 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -2.67 · 95% CI -4.30 to -1.04Based on analysis of covariance, including treatment group, baseline diastolic BP, baseline HbA1c category, site, age category, gender and race
SecondaryChanges in Body Weight at Week 24

Changes from baseline in body weight in placebo and treatment group after 24 weeks of treatment

Time frame:
Baseline and week 24
Reported as:
Least squares mean · kg
Changes in Body Weight at Week 24
kgEGT0001442Placebo
Changes in Body Weight at Week 24-2.95 ± 0.555-1.22 ± 0.592
Statistical analysis
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -1.72 · 95% CI -2.52 to -0.93Based on analysis of covariance, including treatment group, baseline weight, baseline HbA1c category, site, age category, gender and race
SecondaryChange From Baseline in HbA1c Over 96 Weeks Time

Change from baseline in HbA1c level over 96 weeks in placebo and treatment group. The treatment group was treated with EGT0001442 for 24 weeks.

Time frame:
Baseline and up to 96 weeks
Reported as:
Least squares mean · percentage glycated hemoglobin
Change From Baseline in HbA1c Over 96 Weeks Time
percentage glycated hemoglobinEGT0001442Placebo
Week 2-0.10 ± 0.0830.22 ± 0.084
Week 6-0.11 ± 0.1370.49 ± 0.141
Week 12-0.19 ± 0.1800.53 ± 0.186
Week 18-0.28 ± 0.1950.43 ± 0.201
Week 24-0.28 ± 0.1940.51 ± 0.200
Week 36-0.52 ± 0.2020.42 ± 0.209
Week 48-0.45 ± 0.2150.54 ± 0.222
Week 60-0.57 ± 0.2190.41 ± 0.226
Week 72-0.43 ± 0.2130.50 ± 0.220
Week 84-0.60 ± 0.2180.38 ± 0.225
Week 96-0.48 ± 0.2150.54 ± 0.222
Statistical analysis
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -0.32 · 95% CI -0.42 to -0.21Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -0.59 · 95% CI -0.78 to -0.41Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -0.72 · 95% CI -0.96 to -0.48Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -0.71 · 95% CI -0.97 to -0.44Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -0.79 · 95% CI -1.06 to -0.53Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -0.93 · 95% CI -1.21 to -0.66Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level) · Difference of ls means: -0.99 · 95% CI -1.28 to -0.70Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level) · Difference of ls means: -0.98 · 95% CI -1.27 to -0.68Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level) · Difference of ls means: -0.93 · 95% CI -1.22 to -0.64Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -0.98 · 95% CI -1.27 to -0.69Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a 2-sided t-test for the difference in means of change from baseline. Statistical significant is set at 0.05 level.) · Difference of ls means: -1.02 · 95% CI -1.31 to -0.73Based on analysis of covariance, including treatment group, baseline HbA1c, site, age category, gender and race
SecondaryChange From Baseline Over Time in Fasting Plasma Glucose (FPG)

Changes from baseline in FPG in placebo and treatment group over 24 weeks of treatment

Time frame:
24 weeks
Reported as:
Least squares mean · mmol/L
Change From Baseline Over Time in Fasting Plasma Glucose (FPG)
mmol/LEGT0001442Placebo
Week 2-1.39 ± 0.4070.85 ± 0.422
Week 6-1.23 ± 0.4821.22 ± 0.499
Week 12-1.75 ± 0.4890.67 ± 0.507
Week 18-1.87 ± 0.4510.83 ± 0.467
Week 24-1.74 ± 0.4620.89 ± 0.478
Statistical analysis
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a two-sided t-test for the difference in means of change from baseline) · Difference of ls means: -2.24 · 95% CI -2.79 to -1.70Based on analysis of covariance, including treatment group, baseline FPG, baseline HbA1c category, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a two-sided t-test for the difference in means of change from baseline) · Difference of ls means: -2.45 · 95% CI -3.09 to -1.81Based on analysis of covariance, including treatment group, baseline FPG, baseline HbA1c category, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a two-sided t-test for the difference in means of change from baseline) · Difference of ls means: -2.42 · 95% CI -3.06 to -1.77Based on analysis of covariance, including treatment group, baseline FPG, baseline HbA1c category, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a two-sided t-test for the difference in means of change from baseline.) · Difference of ls means: -2.71 · 95% CI -3.30 to -2.11Based on analysis of covariance, including treatment group, baseline FPG, baseline HbA1c category, site, age category, gender and race
  • EGT0001442 vs Placebo · ANCOVA · p = < 0.0001 (The p-value is from a two-sided t-test for the difference in means of change from baseline.) · Difference of ls means: -2.63 · 95% CI -3.24 to -2.02Based on analysis of covariance, including treatment group, baseline FPG, baseline HbA1c category, site, age category, gender and race
SecondaryPercentage of Subjects Achieving HbA1c <7%

The number and percentage of subjects achieving HbA1c response levels \<7% for the FAS using LOCF is reported

Time frame:
Baseline and up to 96 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving HbA1c <7%
ParticipantsEGT0001442Placebo
Week 21413
Week 62215
Week 122717
Week 182914
Week 243314
Week 363514
Week 484120
Week 603918
Week 723917
Week 844316
Week 964414

Adverse events

Collected over The adverse event data were collected from Week 0 (Visit 3) up to Week 97 (Visit 15, 1 week follow-up after completion of study).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EGT00014421/145 (0.7%)3/145 (2.1%)50/145 (34.5%)
Placebo0/141 (0%)12/141 (8.5%)62/141 (44%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventEGT0001442Placebo
CellulitisInfections and infestations2/1450/141
TachycardiaCardiac disorders0/1451/141
Hypertensive crisisCardiac disorders0/1451/141
Respiratory disorderRespiratory, thoracic and mediastinal disorders0/1451/141
PneumoniaInfections and infestations0/1451/141
Urinary tract infectionInfections and infestations0/1451/141
Herpes zosterInfections and infestations0/1451/141
Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1451/141
Spinal column stenosisNervous system disorders0/1451/141
Peripheral nerve lesionNervous system disorders0/1451/141
Most frequent other events
Most frequent other events
EventEGT0001442Placebo
Urinary Tract InfectionInfections and infestations17/14528/141
HypoglycemiaMetabolism and nutrition disorders24/14524/141
HeadacheNervous system disorders7/1459/141
DyslipidaemiaMetabolism and nutrition disorders5/1458/141
HypertriglyceridaemiaMetabolism and nutrition disorders5/1458/141

Baseline characteristics

Age, Continuous
Age, Continuous(years)EGT0001442PlaceboTotal
Mean56.2 ± 10.9454.7 ± 10.3055.4 ± 10.64
Sex: Female, Male
Sex: Female, Male(Participants)EGT0001442PlaceboTotal
Female7891169
Male6750117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EGT0001442PlaceboTotal
Hispanic or Latino129125254
Not Hispanic or Latino161632
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EGT0001442PlaceboTotal
American Indian or Alaska Native112
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American325
White110112222
More than one race312556
Unknown or Not Reported000
Body Mass Index
Body Mass Index(kg/m2)EGT0001442PlaceboTotal
Mean29.7 ± 5.3530.6 ± 5.4130.1 ± 5.39
Baseline HbA1c Category
Baseline HbA1c Category(Participants)EGT0001442PlaceboTotal
< 8.5%87100187
> 8.5%584199
08

Study locations

11 sites
  • Site 5
    Buena Park, California, United States
  • Site 4
    Los Angeles, California, United States
  • Site 3
    Santa Ana, California, United States
  • Site 1
    Hialeah, Florida, United States
  • Site 9
    Berlin, New Jersey, United States
  • Site 7
    Cary, North Carolina, United States
  • Site 6
    Marion, Ohio, United States
  • Site 8
    Munroe Falls, Ohio, United States
  • Site 2
    Portland, Oregon, United States
  • Site 11
    North Richland Hills, Texas, United States
  • Site 7
    San Antonio, Texas, United States
09

References and documents

Publications

  • American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care. 2011 Jan;34 Suppl 1(Suppl 1):S11-61. doi: 10.2337/dc11-S011. No abstract available. PubMed 21193625 ↗
  • Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):31-8. doi: 10.1002/dmrr.532. PubMed 15624123 ↗
  • Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010 Oct;33(10):2217-24. doi: 10.2337/dc10-0612. Epub 2010 Jun 21. PubMed 20566676 ↗
  • Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008 Jun;57(6):1723-9. doi: 10.2337/db07-1472. Epub 2008 Mar 20. PubMed 18356408 ↗
  • Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009 May;85(5):520-6. doi: 10.1038/clpt.2008.251. Epub 2009 Jan 7. PubMed 19129748 ↗
  • Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 May;85(5):513-9. doi: 10.1038/clpt.2008.250. Epub 2009 Jan 7. Erratum In: Clin Pharmacol Ther. 2009 May;85(5):558. PubMed 19129749 ↗
  • Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. PubMed 20205482 ↗
  • Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003 Nov;14(11):2873-82. doi: 10.1097/01.asn.0000092790.89332.d2. PubMed 14569097 ↗
  • Sicree, R., Shaw, J., and Zimmet, P. (2010). The Global Burden - Diabetes and Impaired Glucose Tolerance (Baker IDI Heart and Diabetes Institute).
  • van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet. 2002 Dec;111(6):544-7. doi: 10.1007/s00439-002-0820-5. Epub 2002 Sep 27. PubMed 12436245 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Nov 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2021, 7 years 7 months after primary completion. A results delay was requested in Jul 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2011
First posted
Jun 21, 2011
Start
Dec 2011
Primary completionActual
Nov 2013
CompletionActual
Dec 2013
Results delay requested
Jul 23, 2014
Results first posted
Jun 16, 2021
Last update
Jul 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01377844
Lead sponsor
Theracos
Responsible party
Sponsor
First posted
Jun 21, 2011
Start date
Dec 2011
Primary completion
Nov 2013
Completion
Dec 2013
Results posted
Jun 16, 2021
Last update
Jul 1, 2021

Study contacts

Mason W Freeman, M.D.
study director · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexagliflozin

Start the discussion